Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. These findings highlight the current lack of robust clinical evidence supporting CBD as an effective treatment for fibromyalgia-related pain. Patients and clinicians should weigh this evidence carefully before pursuing CBD as a primary pain management strategy.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence base for cannabidiol efficacy in fibromyalgia, a condition where pharmacological options remain limited and patient outcomes suboptimal with conventional treatments. The double-blind, placebo-controlled design directly addresses the gap between widespread clinical use of CBD for fibromyalgia pain and the absence of high-quality efficacy data, enabling evidence-based treatment recommendations. If CBD demonstrates superiority over placebo, it could establish a new therapeutic option for fibromyalgia patients; if negative, it would redirect clinical practice away from an unsupported intervention.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomised controlled trial provides meaningful evidence for CBD’s role in fibromyalgia management, though several factors warrant careful interpretation in clinical practice. The single-centre design and relatively homogeneous Danish population limit generalisability to broader patient populations with varying genetics, comorbidities, and polypharmacy profiles. The trial’s primary outcome measures and follow-up duration are important considerations, as fibromyalgia symptoms often fluctuate and placebo response rates are notoriously high in pain conditions, potentially masking true treatment effects. When counselling fibromyalgia patients about CBD, clinicians should position this evidence within the context of multimodal management including exercise, sleep optimisation, and psychosocial support rather than as monotherapy. Given the heterogeneity of fibromyalgia presentations and individual cannabinoid sensitivity, a cautious N-of-1 approach with clear outcome metrics and regular reassessment remains the most defensible clinical strategy until larger, multicentre trials establish optimal dosing
|